Tyrosine Kinase Inhibitors: all 10,469 studies that test it

Page 13 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.

• Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPiNot yet recruitingNCT06161272Phase 2
• Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)RecruitingNCT06160791Phase 2
• Pacritinib in CMMLRecruitingNCT06159491Phase 1/2
• Cabozantinib With Ifosfamide in Relapsed/Refractory SarcomasRecruitingNCT06156410Phase 1
• Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain MetastasesRecruitingNCT06152822Phase 2
• Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal CancerRecruitingNCT06148402Phase 2
• A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung CancerRecruitingNCT06147570Phase 2
• Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid CancerNot yet recruitingNCT06146985Phase 2
• Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingNCT06145308Phase 2
• A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.Not yet recruitingNCT06142617Phase 2
• Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung CancerRecruitingNCT06141226Phase 2
• Apatinib Combined With Camrelizumab in Treating Participants With Advanced ChordomaRecruitingNCT06140732Phase 2
• The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.Not yet recruitingNCT06140576Phase 1/2
• A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)RecruitingNCT06136559Phase 3
• A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell LymphomaRecruitingNCT06136351Phase 2
• Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract CancerNot yet recruitingNCT06134193Phase 2
• Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid TumorsRecruitingNCT06128148Phase 1
• Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic SyndromeRecruitingNCT06128070Phase 2
• Tucidinostat Plus Apatinib for Advanced OsteosarcomaNot yet recruitingNCT06125171Phase 2
• A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingNCT06124157Phase 2
• A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)RecruitingNCT06122831Phase 1/2
• Precision Cancer Therapy in Rare CancersRecruitingNCT06119789Phase 2
• Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal NecrolysisRecruitingNCT06119490Early Phase 1
• Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal CancerRecruitingNCT06118762Phase 4
• Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With TofacitinibRecruitingNCT06114407Phase 2
• ToFAcitinib in Early Active Axial SpondyloarThritis:RecruitingNCT06112665Phase 4
• Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)RecruitingNCT06112340Phase 2/3
• A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic CancerRecruitingNCT06111274Phase 2
• A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI TherapyNot yet recruitingNCT06110663Phase 3
• A Study of Surufatinib in the Treatment of Advanced Soft Tissue SarcomaNot yet recruitingNCT06110650Not applicable
• The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLCRecruitingNCT06109558Phase 1/2
• Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib TreatmentRecruitingNCT06106802Phase 2
• Global Trial in APG2575 for Patients With CLL/SLLRecruitingNCT06104566Phase 3
• Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative ColitisRecruitingNCT06095596Not applicable
• Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced CancerNot yet recruitingNCT06094868Phase 2
• Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct AdenocarcinomaRecruitingNCT06092645Phase 2
• Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLCRecruitingNCT06092086Phase 2
• Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 DeficiencyRecruitingNCT06090669Phase 1
• A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical ResectionNot yet recruitingNCT06089382Phase 3
• TGRX-678 US Phase I for Chronic Myelogenous Leukemia PatientsRecruitingNCT06088888Phase 1
• A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCLRecruitingNCT06086197Phase 2
• Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric CancerRecruitingNCT06085755Phase 1/2
• Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic LeukemiaRecruitingNCT06082934Phase 1/2
• Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone LymphomaRecruitingNCT06082102Phase 3
• Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance TreatmentNot yet recruitingNCT06081595Phase 2
• MAP-guided Preemptive Therapy of aGvHD by RuxolitinibNot yet recruitingNCT06075225Phase 2
• A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerRecruitingNCT06072781Phase 3
• A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or FusionsRecruitingNCT06072586Early Phase 1
• Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer PatientsRecruitingNCT06071013Phase 1/2
• bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular CarcinomaRecruitingNCT06070636Not applicable
• Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell CancerNot yet recruitingNCT06067776Phase 1
• Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/ContusionsRecruitingNCT06065046Phase 2
• Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR MutationsRecruitingNCT06062823Phase 2
• Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid CancerNot yet recruitingNCT06062563Not applicable
• bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCCRecruitingNCT06061276Not applicable
• Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCTRecruitingNCT06061094Phase 2
• Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT06054776Phase 2
• Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 MutationsNot yet recruitingNCT06054191Phase 2
• Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell CarcinomaRecruitingNCT06053658Phase 2
• Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)RecruitingNCT06052618Phase 2
• Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic CancerRecruitingNCT06051851Phase 2
• A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)RecruitingNCT06051409Phase 3
• A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological MalignanciesRecruitingNCT06049667Phase 1
• A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung CancerRecruitingNCT06046495Phase 1
• Effectiveness of Tofacitinib in Systemic SclerosisRecruitingNCT06044844Phase 2
• Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung CanceRecruitingNCT06043973Phase 3
• Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's TransformationRecruitingNCT06043674Phase 2
• A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid TumorsRecruitingNCT06037317Phase 1
• Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast CancerRecruitingNCT06035679Not applicable
• Gemox Combined With Anlotinib and Sintilimab in Advanced cHCC-ICCNot yet recruitingNCT06033118Phase 1/2
• Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors (CASTLE-11)RecruitingNCT06032845Phase 2
• Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant TreatmentNot yet recruitingNCT06032728Not applicable
• Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint InhibitorsNot yet recruitingNCT06031480Phase 2
• IN10018 Combination Therapy in Treatment-naïve ES-SCLCRecruitingNCT06030258Phase 1/2
• Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR MutationsNot yet recruitingNCT06029816Phase 2
• Zanubrutinib and Tafasitamab in Mantle Cell LymphomaRecruitingNCT06029309Phase 1/2
• Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC PatientsNot yet recruitingNCT06028633Phase 2
• KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsRecruitingNCT06026410Phase 1
• Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid TumorsRecruitingNCT06022289Phase 2
• Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid LeukemiaRecruitingNCT06022003Phase 2
• The Safety and Efficacy of Zanubrutinib in Refractory/Relapsed Autoimmune Hemolytic AnemiaRecruitingNCT06021977Phase 2
• Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib MonotherapyNot yet recruitingNCT06020989Phase 2
• The Efficacy and Safety of KN046 Combined With AxitinibRecruitingNCT06020352Phase 2/3
• Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II StudyRecruitingNCT06018714Phase 2
• Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility StudyRecruitingNCT06016387Phase 2
• IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian CancerRecruitingNCT06014528Phase 2
• A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia AreataRecruitingNCT06012240Phase 3
• Tofacitinib Associated With Meglumine Antimoniate in Cutaneous LeishmaniasisNot yet recruitingNCT06011343Phase 2/3
• Fruquintinib With mFOLFOX6/FOLFIRI as First-Line Therapy for Conversion Surgery in mCRCRecruitingNCT06010888Phase 2
• A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors PatientsRecruitingNCT06010342Phase 2
• A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLCRecruitingNCT06010329Phase 2
• Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell TransplantationRecruitingNCT06008808Phase 1
• Neratinib in Combination With Ruxolitinib in Patients With mTNBCRecruitingNCT06008275Early Phase 1
• A Study of Avutometinib and Defactinib in People With Thyroid CancerRecruitingNCT06007924Phase 2
• Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune ThrombocytopeniaRecruitingNCT06004856Phase 3
• Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast CancerNot yet recruitingNCT06000033Phase 2
• A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)RecruitingNCT05999149Phase 3
• Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS LymphomaRecruitingNCT05998642Phase 2
• A Single Arm, Phase II Exploratory Clinical Study of Pemitinib in Advanced Gastric Cancer With Previous Standard Therapy Failure the FGFR VariantNot yet recruitingNCT05997459Phase 2
• Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal CarcinomaNot yet recruitingNCT05996484Phase 2

← Tyrosine Kinase Inhibitors overview